brinzolamide suspension/ drops
actavis pharma, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375 times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conduc
brinzolamide suspension/ drops
sandoz inc - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conduct
brinzolamide suspension/ drops
oceanside pharmaceuticals. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conducted in
simbrinza eye drops suspension 10 mgml + 2 mgml
novartis (singapore) pte ltd - brimonidine tartrate; brinzolamide - suspension, sterile - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml
simbrinza
alcon laboratories (sa) (pty) ltd - brinzolamide, brimonidine tartrate - eye drops, suspension - each ml contains; brinzolamide 10mg and brimonidine tartrate 2mg.
brinzolamide timolol moosmann drops eye (suspension)
lusomedicamenta sociedade tecnica farmaceutica - brinzolamide, timolol (timolol maleate) - drops eye (suspension) - 10mg/ml+ 5mg/ml
brinzolamide 10mg/ml eye drops suspension
wockhardt uk ltd - brinzolamide - eye drops, suspension - 10mg/ml - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors - it is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues
brinzolamide 10mg/ml eye drops, suspension
teva uk limited, eastbourne - brinzolamide - eye drops, suspension - 10mg/ml - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors - it is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues
brinzolamide 10mg/ml eye drops, suspension
generics [uk] limited t/a mylan - brinzolamide - eye drops, suspension - 10mg/ml - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors - it is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues
brinzolamide 10mg/ml eye drops, suspension
pharmathen s.a - brinzolamide - eye drops, suspension - 10mg/ml - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors - it is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues